Erratum: Aktuelle Diagnostik und Therapie der Multiplen Sklerose (Deutsche Medizinische Wochenschrift (2012) 137:20 (1072) DOI: 10.1055/s-0032-1304927);Erratum: 2012: Update on diagnosis and treatment of multiple sclerosis (Deutsche Medizinische Wochenschrift (2012) 137:20 (1072) DOI: 10.1055/s-0032-1304927);2012: Update on diagnosis and treatment of multiple sclerosis;Aktuelle diagnostik und therapie der multiplen sklerose

Deutsche Medizinische Wochenschrift

Volumn 137, Issue 17, 2012, Pages 894-899

  Havla, J ^a   Kumpfel T ^a   Hohlfeld, R ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

diagnostic criteria; immunomodulatory treatment; Multiple Sclerosis

Indexed keywords

MULTIPLE SCLEROSIS; REVIEW;

EID: 84860130249     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0032-1301859     Document Type: Erratum

References (23)

1. Goodman AD, Brown TR, Edwards KR et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol: 2011; 68 494 502
2. Grauer O, Offenhausser M, Schmidt J et al. Glukokortikosteroid-Therapie bei Optikusneuritis und Multipler Sklerose. Evidenz aus klinischen Studien und praktischen Empfehlungen. Nervenarzt: 2001; 72 577 589 (Pubitemid 32717639)
3. Havla J, Gerdes LA, Meinl I et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol: 2011; 258 1665 1669
4. Havla J, Pellkofer HL, Meinl I et al. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol: 2012; 69 262 264
5. Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol: 2011; 257 580 583
6. Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Europ Neurol: 2006; 56 78 105 (Pubitemid 44492163)
7. Klotz L, Gold R, Hemmer B et al. Diagnostik der Multiplen Sklerose 2010. Revision der McDonald-Kriterien. Nervenarzt: 2011; 82 1302 1309
8. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology: 1996; 46 907 911
9. Lucas RM, Ponsonby AL, Dear K et al. Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology: 2011; 77 371 379
10. Martinelli V, Cocco E, Capra R et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology: 2011; 77 1887 1895
11. Mauch E, Zwanzger J, Hettich R et al. Immunadsorption bei steroidrefraktärem Schub der Multiplen Sklerose. Klinische Erfahrung bei 14 Patienten. Nervenarzt: 2011; 12 1590 1595
12. Mowry EM, James JA, Krupp LB et al. Vitamin D status and antibody levels to common viruses in pediatric-onset multiple sclerosis. Mult Scler: 2011; 17 666 671
13. O'Connor PW, Goodman A, Kappos L et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology: 2011; 76 1858 1865
14. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med: 2012; 366 339 347
15. Polman CH, Bertolotto A, Deisenhammer F et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol: 2010; 9 740 750
16. Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol: 2011; 69 292 302
17. Sailer M, Fazekas F, Gass A et al. Zerebrale und spinale MRT-Untersuchung bei Patienten mit klinisch isoliertem Syndrom oder gesicherter Multipler Sklerose. Rofo: 2008; 180 994 1001
18. Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature: 2011; 476 214 219
19. Schroder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert Rev Neurother: 2009; 9 1331 1339
20. Smolders J, Menheere P, Kessels A et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler: 2008; 14 1220 1224
21. Stroet A, Hemmelmann C, Starck M et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord: 2012; 5 75 79
22. Tumani H, Deisenhammer F, Giovannoni G et al. Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. Ann Neurol: 2011; 70 520
23. Wade DT, Collin C, Stott C et al. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler: 2011; 16 707 714